Edition:
United States

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

63.59USD
20 Oct 2017
Change (% chg)

$0.12 (+0.19%)
Prev Close
$63.47
Open
$63.69
Day's High
$63.90
Day's Low
$63.40
Volume
1,140,077
Avg. Vol
696,964
52-wk High
$64.75
52-wk Low
$43.14

Select another date:

Thu, Oct 12 2017

BRIEF-Baxter provides update on Puerto Rico recovery status post Hurricane Maria

* Baxter provides update on Puerto Rico recovery status post Hurricane Maria

BRIEF-Baxter International Inc - ‍launches DeviceVue Advanced Asset Tracking System for Sigma Spectrum Infusion System​

* Baxter International Inc - ‍launches DeviceVue Advanced Asset Tracking System for Sigma Spectrum Infusion System​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Baxter International ‍announces commercial launch of new indication for oXiris set​

* Baxter launches first 3-in-1 set for use in continuous renal replacement therapy and sepsis management protocols

BRIEF-Baxter and MATTER Healthcare on patient-driven innovation

* Baxter and MATTER Healthcare Incubator Partner on patient-driven innovation

Big-name U.S. hedge funds shed healthcare stocks during the rally in second-quarter

NEW YORK Several big-name hedge fund investors trimmed their stakes in healthcare companies in the second quarter as the sector led the broad U.S. stock market higher, rallying amid a Republican effort to repeal and replace President Obama's signature healthcare law.

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON, July 20 Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

BRIEF-Baxter appoints Cathy R. Smith to its board

* Appointed Cathy R. Smith, executive vice president and cfo of target corp, to its board ​

BRIEF-Baxter announces agreement with Dorizoe Lifesciences to further expand generic injectables pipeline

* Baxter announces agreement with dorizoe lifesciences to further expand generic injectables pipeline

BRIEF-Baxter announces U.S. FDA approval, commercial launch of ready-to-use clindamycin injection in saline

* Baxter announces U.S. FDA approval and commercial launch of ready-to-use clindamycin injection in saline

Select another date: